drugset / Trial / NCT01961063
Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This pilot clinical trial studies gene therapy after frontline chemotherapy in treating patients with acquired immune deficiency syndrome (AIDS)-related non-Hodgkin lymphoma (NHL). Placing genes for anti-human immunodeficiency virus (HIV) ribonucleic acid (RNA) into stem/progenitor cells may make the body build an immune response to AIDS. Giving the chemotherapy drug busulfan before gene therapy can help gene-modified cells engraft and work better.
Timeline
- Start
- 2015-12-31
- Primary completion
- 2026-08-05
- Completion
- 2026-08-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Busulfan | Small molecule | — | Intravenous |
| Subject | rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells | Unknown | — | Intravenous |